Production Of GSK's Ziagen HIV Oral Liquid Medicine

A GlaxoSmithKline Canada Inc. employee labels and packages bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
A GlaxoSmithKline Canada Inc. employee labels and packages bottles of Ziagen, an HIV oral liquid medication, on the packaging line at the company's Canadian headquarters in Mississauga, Ontario, Canada, on Monday, Dec. 13, 2010. Global sales of existing HIV medicines will peak at $12 billion in 2012, then halve by 2019 as patent expiries increase competition from generic drugs, according to a report by Datamonitor Group earlier this year. Photographer: Norm Betts/Bloomberg via Getty Images
Production Of GSK's Ziagen HIV Oral Liquid Medicine
ライセンスの購入
どんな用途に素材を使えますか?
¥38,500
JPY

詳細

制限:
商業目的またはプロモーション目的で使用する場合は、ゲッティ イメージズのオフィスへお問い合わせください。For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
クレジット:
Bloomberg / 寄稿者
報道写真番号:
107630293
コレクション:
Bloomberg
作成日:
2010年12月13日(月)
アップロード日:
ライセンスタイプ:
リリース情報:
リリースされていません。 詳細情報
ソース:
Bloomberg
オブジェクト名:
GLAXO